Massachusetts Biotech Funding Sees Divergent Trends as Early-Stage Investment Wanes Amid Rising China Competition
admin A recent comprehensive report by MassBio, a prominent trade organization representing the Massachusetts life sciences...
fda
FDA extends review of Capricor cell therapy; Pain drug startup to go public
Washington D.C. – August 24, 2026 – The biopharmaceutical landscape is abuzz with significant regulatory...
Regenxbio’s RGX-121 Gene Therapy for Hunter Syndrome Faces New Clinical Hold Amidst Troubled Regulatory Path
The development journey for RGX-121, Regenxbio’s investigational gene therapy designed as a one-time treatment for...
Pharma marketers need a share-of-answer strategy before AI spend
The pharmaceutical marketing landscape is undergoing a profound transformation, driven by the rapid integration of...
Moderna’s Individualized mRNA Cancer Vaccine Demonstrates Significant Efficacy in Interim Trial Data, Bolstering Shares and Oncology Hopes
An interim analysis of a pivotal clinical trial for Moderna’s individualized mRNA cancer treatment, intismeran...
Biopharma Sector Buzzes with Activist Demands, AI Partnerships, and Novel Therapeutic Advancements
The biopharmaceutical landscape is currently experiencing a dynamic period, marked by significant strategic maneuvers from...
The Battle for the Billion-Dollar Weight Loss Market: Eli Lilly and Novo Nordisk Navigate Innovation, Affordability, and Perception
The pharmaceutical titans Eli Lilly and Novo Nordisk are locked in an intense, high-stakes competition...
Ultragenyx, after setbacks, nabs first gene therapy approval
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Genglycos, Ultragenyx Pharmaceutical...
Moderna’s Intismeran Achieves Landmark Phase 3 Success in Melanoma, Igniting a Historic Stock Surge and Revitalizing Personalized Cancer Vaccine Hopes
After a challenging period that saw its stock price plummet from pandemic-era highs, Moderna, in...
Regeneron to challenge Ipsen as FDA clears bone disease drug
The U.S. Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ Pasatru (garetosmab),...
